Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi | Zendy

Austin A. Robinson | Zendy; Cory R. Trankle | Zendy; Grayson Eubanks | Zendy; Christopher Schumann | Zendy; Paul A. Thompson | Zendy; Ryan Wallace | Zendy; Shouri Gottiparthi | Zendy; Benjamin Ruth | Zendy; Christopher M. Kramer | Zendy; Michael Salerno | Zendy; Kenneth C. Bilchick | Zendy; Cody S Deen | Zendy; Michael C. Kontos | Zendy; John Dent | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi

Author(s) -

Austin A. Robinson,

Cory R. Trankle,

Grayson Eubanks,

Christopher Schumann,

Paul A. Thompson,

Ryan Wallace,

Shouri Gottiparthi,

Benjamin Ruth,

Christopher M. Kramer,

Michael Salerno,

Kenneth C. Bilchick,

Cody S Deen,

Michael C. Kontos,

John Dent

Publication year - 2020

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2020.0652

Subject(s) - medicine , warfarin , interquartile range , hazard ratio , cohort , cardiology , stroke (engine) , atrial fibrillation , surgery , confidence interval , mechanical engineering , engineering

Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of direct oral anticoagulants (DOACs) for this indication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research